Modeling HIV Pre-Exposure Prophylaxis

Area of Science:

• Pharmacology and Infectious Diseases
• Computational Modeling in Drug Development
• HIV Prevention Research

Background:

• Human Immunodeficiency Virus (HIV) remains a significant global health challenge.
• Pre-exposure prophylaxis (PrEP) is a key strategy for preventing HIV transmission in at-risk individuals.
• Current PrEP options, like daily oral Truvada, face adherence challenges, especially in resource-limited settings.

Purpose of the Study:

• To review the current landscape of pharmacokinetic/pharmacodynamic (PK/PD) and quantitative systems pharmacology (QSP) modeling for HIV PrEP.
• To highlight existing and emerging antiretroviral agents and delivery systems for PrEP.
• To discuss modeling challenges and opportunities in PrEP development, including adherence and novel formulations.

Main Methods:

• Review of existing literature on PK/PD and QSP models applied to HIV PrEP.
• Analysis of modeling approaches for current and investigational PrEP compounds and formulations.
• Discussion of modeling considerations for adherence, novel administration routes, and viral dynamics.

Main Results:

• PK/PD and QSP modeling are essential tools for understanding drug behavior in PrEP regimens.
• Modeling aids in the evaluation of new PrEP compounds, delivery systems (e.g., implants, depot injections, gels, rings), and administration routes.
• Computational modeling can optimize PrEP development by reducing trial duration, cost, and patient burden.

Conclusions:

• Modeling plays a vital role in advancing HIV PrEP research and development.
• Further development of PK/PD and QSP models is needed to support novel long-acting and on-demand PrEP formulations.
• Modeling insights are critical for overcoming challenges related to adherence and optimizing efficacy in diverse populations.